08:00 , Dec 3, 2012 |  BioCentury  |  Emerging Company Profile

Lipigon: LPL protectorate

Lipoprotein lipase has long been a desirable target to treat atherosclerosis, but direct-acting activators of the enzyme have failed. Lipigon Pharmaceuticals AB is taking a different tack, developing small molecules that protect the enzyme from...
07:00 , Jul 15, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Apolipoprotein C-II (APOC2; APOCII) and serum amyloid A (SAA) as biomarkers of neonatal sepsis and necrotizing enterocolitis (NEC) infections Serum...